Extending the reach of nilotinib in chronic myeloid leukemia

Mauro, Michael J.

doi:10.3324/haematol.2014.106195

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Selective BCR-ABL tyrosine kinase inhibitor (TKI) has superseded allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML) 1 . As a first-line treatment, imatinib reduced the number of allo-HSCTs due to its 98%, 92%, and 83% efficacy in channeling the chronic phase of disease toward complete hematologic responses (CHRs), major cytogenetic responses (MCRs), and complete cytogenetic responses (CCRs), respectively 2 , 3 . Based on the guidelines, the indications of allo-HSCT in the TKI era are resistance or intolerance of patients to second-generation TKIs, the existence of T315I mutation after examining more available treatment options, and the classification of transplant and illness risk 4 .…”

Section: Introductionmentioning

confidence: 99%

Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up

et al. 2023

View full text Add to dashboard Cite

Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retrospectively analyzed the outcomes of 204 patients with sibling donors who received peripheral stem cells and underwent allo-HSCT of chronic phase I (CP1) in the pre- and post-TKI era at Shariati Hospital in Tehran, Iran, from 1998 to 2017 and followed up till the end of 2021. The median follow-up time for all patients was 8.7 (SD = 0.54) years. Fifteen-year overall survival (OS), disease-free survival (DFS), graft-versus-host disease-free relapse-free survival (GRFS), relapse, and non-relapse mortality (NRM) incidence were 65.70%, 57.83%, 17.56%, 13.17%, and 28.98%, respectively. Using multivariable analyses, the only risk factor increasing the hazard of death was the time between diagnosis to allo-HSCT greater than 1 year compared to this time less than 1 year by 74% [hazard ratio (HR) = 1.74, P = 0.039]. Also, age is a significant risk factor for DFS (HR = 1.03, P = 0.031). Our findings suggested that allo-HSCT is still an important treatment option for CP1 patients, especially those resistant to TKI treatment. TKI consumption can have a desirable effect on NRM after allo-HSCT for CP1 CML.

show abstract

Section: Introductionmentioning

confidence: 99%